44 related articles for article (PubMed ID: 38748549)
1. Comparison of direct oral anticoagulants and warfarin in chronic limb-threatening ischemia.
Rockhold M; Kunkel L; Lacoste JL; Szymanski T; Rothenberg P; Zimmerman P; Minc S
J Vasc Surg; 2024 Jun; 79(6):1466-1472.e1. PubMed ID: 38278371
[TBL] [Abstract][Full Text] [Related]
2. Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era.
Chatani R; Yamashita Y; Morimoto T; Kaneda K; Mushiake K; Kadota K; Nishimoto Y; Ikeda N; Kobayashi Y; Ikeda S; Kim K; Inoko M; Takase T; Tsuji S; Oi M; Kimura T;
Eur J Intern Med; 2024 May; 123():72-80. PubMed ID: 38278660
[TBL] [Abstract][Full Text] [Related]
3. Lower-adherence direct oral anticoagulant use is associated with increased risk of thromboembolic events than warfarin.
Bawa D; Darden D; Ahmed A; Garg J; Karst E; Kabra R; Pothineni K; Gopinathannair R; Mansour M; Winterfield J; Lakkireddy D
J Interv Card Electrophysiol; 2024 Jun; 67(4):709-718. PubMed ID: 37556090
[TBL] [Abstract][Full Text] [Related]
4. Design and Rationale for the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices (DOAC LVAD) Study.
Dimond M; Looby M; Shah B; Sinha SS; Isseh I; Rollins AT; Abdul-Aziz AA; Kennedy J; Tang DG; Klein KM; Casselman S; Vermeulen C; Sheaffer W; Snipes M; O'connor CM; Shah P
J Card Fail; 2024 Jun; 30(6):819-828. PubMed ID: 37956897
[TBL] [Abstract][Full Text] [Related]
5. Impact of direct-acting oral anticoagulants and warfarin on postendoscopic GI bleeding and thromboembolic events in patients undergoing elective endoscopy.
Tien A; Kwok K; Dong E; Wu B; Chung J; Chang J; Reynolds K
Gastrointest Endosc; 2020 Aug; 92(2):284-292.e2. PubMed ID: 32126220
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Warfarin Home INR Monitoring vs Office-Based Monitoring: a Retrospective Claims-Based Analysis.
Van Beek A; Moeyaert M; Ragheb B; Price E; MacEwan JP; Ahmed N; Ansell J
J Gen Intern Med; 2024 May; 39(7):1127-1134. PubMed ID: 38100006
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices: The DOAC LVAD Study.
Shah P; Looby M; Dimond M; Bagchi P; Shah B; Isseh I; Rollins AT; Abdul-Aziz AA; Kennedy J; Tang DG; Klein KM; Casselman S; Vermeulen C; Sheaffer W; Snipes M; Sinha SS; O'Connor CM
JACC Heart Fail; 2024 May; ():. PubMed ID: 38795110
[TBL] [Abstract][Full Text] [Related]
8. A Pilot Study Describing DOAC Level Results and Association With Clinical Outcomes.
Gochnauer B; Rodino A; Russell S; Bradley K
J Pharm Pract; 2024 Jun; ():8971900241262363. PubMed ID: 38884944
[No Abstract] [Full Text] [Related]
9. Deferring diagnostic evaluation of suspected deep vein thrombosis using direct oral anticoagulant or low-molecular-weight heparin as a single dose anticoagulant: A prospective real-world study in a regionwide care pathway.
Luu IHY; Appelboom Y; Willems JIA; Gielen RCAM; Lobbes MBI; Külcü K; Ten Cate H; Peeters J; Palmen J; Buijs J; Jie KG; van Kampen RJW; Mostard GJM; van Twist DJL
Thromb Res; 2024 Jun; 240():109059. PubMed ID: 38850808
[TBL] [Abstract][Full Text] [Related]
10. Potential interactions between medications for rate control and direct oral anticoagulants: population-based cohort and case-crossover study.
Wong AY; Warren-Gash C; Bhaskaran K; Leyrat C; Banerjee A; Smeeth L; Douglas IJ
Heart Rhythm; 2024 Jun; ():. PubMed ID: 38909715
[TBL] [Abstract][Full Text] [Related]
11. Association between genetic polymorphisms in fibrinogen genes and bleeding risk in patients treated with direct oral anticoagulants.
Choi KH; Yee J; Song TJ; Park J; Gwak HS
Ann Acad Med Singap; 2023 Jul; 52(7):340-347. PubMed ID: 38904499
[TBL] [Abstract][Full Text] [Related]
12. Direct Oral Anticoagulants: Navigating Through Clinical Challenges.
Ioannou M; Leonidou E; Chaziri I; Mouzarou A
Cardiovasc Drugs Ther; 2024 Jun; 38(3):637-650. PubMed ID: 37552381
[TBL] [Abstract][Full Text] [Related]
13. Management of patients with proximal femur fractures under DOACs.
Maegele M
Eur J Trauma Emerg Surg; 2024 Apr; 50(2):359-366. PubMed ID: 38400927
[TBL] [Abstract][Full Text] [Related]
14. The DOAC (direct oral anticoagulant) Dipstick reliably excludes residual FXa inhibitors levels in the preoperative setting.
Vassart J; Tafur A; Durante M; Boucher AY; Morimont L; Walenga JM; Harenberg J; Douxfils J
Thromb Res; 2024 Jul; 239():109023. PubMed ID: 38761550
[No Abstract] [Full Text] [Related]
15. Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin in Patients With Obesity and Venous Thromboembolism: A Retrospective Analysis.
Tu ZH; Perez AD; Diaz TE; Loop MS; Clarke M
Tex Heart Inst J; 2024 May; 51(1):. PubMed ID: 38748549
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Perales IJ; San Agustin K; DeAngelo J; Campbell AM
Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
[No Abstract] [Full Text] [Related]
17. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.
Coons JC; Albert L; Bejjani A; Iasella CJ
Pharmacotherapy; 2020 Mar; 40(3):204-210. PubMed ID: 31968126
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
